Ipca Laboratories cash flow

Latest FY26

Cash from operations: ₹1,142cr−13.6% on FY25
Capital spending: ₹652cr−15.9% on FY25
Free cash flow: ₹490cr−10.3% on FY25
Cash from financing: −₹754cr−₹283 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	418	398	357	262
	—	0.0	0.0	11.1	0.0
	—	75.9	84.9	138	45.5
	—	−31.7	−35.1	−62.9	−79.4
	—	−0.0	5.7	−7.2	1.4
	—	0.8	2.1	3.1	0.0
	—	48.8	10.2	−7.2	18.7
	—	46.0	265	−3.7	−12.7
	—	−281	−2.8	−64.4	0.0
	—	−171	−91.6	−94.7	115
	—	−48.9	−218	−75.8	−68.1
	—	2.6	36.4	8.5	12.2
	—	−3.0	−3.7	−11.6	−0.0
	—	−11.2	92.4	−59.6	40.4
	—	−49.1	−8.7	47.7	−10.3
	—	66.8	72.7	21.5	−32.4
	—	45.6	−42.9	85.3	5.9
	—	2.5	−35.5	−3.1	−17.0
	—	−0.2	−0.4	−0.7	−1.7
	—	−130	12.9	225	1.2
	—	1.6	9.5	−108	4.3
Cash from operating activities
	1,814	1,573	1,131	843	745
	—	−16.6	551	398	284
	—	1,556	1,683	1,241	1,029
	—	414	361	296	224
	—	1,142	1,321	945	806
Cash from investing activities
	—	652	776	411	494
	—	−3.7	5.3	8.6	36.2
	—	0.0	0.1	0.0	0.0
	—	339	0.0	0.0	0.0
	—	0.0	0.0	64.8	0.0
	—	0.0	27.2	25.1	45.3
	—	0.0	0.0	1,543	10.6
	—	3.5	0.0	0.0	0.0
	—	0.0	6.3	0.0	0.0
	—	27.9	24.8	−21.2	173
	—	11.3	32.1	2.0	137
	—	31.5	24.0	80.9	54.2
	—	51.8	−97.1	510	−229
	—	−247	−870	−1,292	−725
Cash from financing activities
	—	−77.8	218	−180	686
	—	525	312	177	28.3
	—	22.4	18.0	10.7	7.5
	—	—	—	2.5	1.7
	—	75.7	70.2	132	39.8
	—	52.4	101	50.7	101
	—	−754	−283	−553	507
	—	142	169	−900	588
	—	142	169	−900	588
	—	—	—	756	1,579
Reference items
	2,232	1,979	1,726	1,321	927
	22.0%	20.5%	19.3%	17.2%	14.8%
	490	490	546	533	311
	—	−184	390	332	—
	₹19.30	₹19.30	₹21.51	₹21.02	₹12.27
	100.01×	—	—	—	—
	—	0.96×	1.68×	1.81×	1.68×
	—	414	361	296	224
	—	75.7	70.2	132	39.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IPCALAB₹1,930.50

Ipca Laboratories Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM JBCHEPHARM ABBOTINDIA AJANTPHARM ANTHEM GLAXO MEDANTAMcap ₹48,977 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	261.6	357.2	397.8	418.1	—
+ Impairment Loss / (Reversal)	0.0	11.1	0.0	0.0	—
+ Finance Costs	45.5	138.3	84.9	75.9	—
+ Interest Income	-79.4	-62.9	-35.1	-31.7	—
+ Fair Value (Gains) / Losses	1.4	-7.2	5.7	-0.0	—
+ Share-based Payments	0.0	3.1	2.1	0.8	—
+ Unrealised FX (Gain) / Loss	18.7	-7.2	10.2	48.8	—
+ Other Non-cash Items	-12.7	-3.7	265.1	46.0	—
+ Other — Cash Effects are Investing / Financing	0.0	-64.4	-2.8	-280.6	—
Changes in Working Capital
+ Inventories	114.6	-94.7	-91.6	-170.6	—
+ Trade Receivables — Current	-68.1	-75.8	-217.7	-48.9	—
+ Other Financial Assets — Current	12.2	8.5	36.4	2.6	—
+ Other Financial Assets — Non-current	-0.0	-11.6	-3.7	-3.0	—
+ Other Current Assets	40.4	-59.6	92.4	-11.2	—
+ Other Non-current Assets	-10.3	47.7	-8.7	-49.1	—
+ Trade Payables — Current	-32.4	21.5	72.7	66.8	—
+ Other Financial Liabilities — Current	5.9	85.3	-42.9	45.6	—
+ Other Current Liabilities	-17.0	-3.1	-35.5	2.5	—
+ Other Non-current Liabilities	-1.7	-0.7	-0.4	-0.2	—
+ Provisions — Current	1.2	224.8	12.9	-130.0	—
+ Provisions — Non-current	4.3	-108.3	9.5	1.6	—
Cash from Operating Activities
Profit Before Tax (per I/S)	745.3	842.7	1,131.1	1,572.5	1,814.1
+ Total Adjustments (incl. Working Capital)	284.2	398.3	551.4	-16.6	—
Cash from Operations (pre-tax)	1,029.5	1,241.0	1,682.6	1,555.9	—
+ Income Taxes Paid	223.7	296.3	361.3	414.0	—
Cash from Operating Activities	805.8	944.7	1,321.3	1,142.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	494.5	411.3	775.5	652.3	—
+ Disp of Fixed Assets	36.2	8.6	5.3	-3.7	—
+ Acq of Biological Assets	0.0	0.0	0.1	0.0	—
+ Disp of Other Long-term Assets	0.0	0.0	0.0	339.0	—
+ Sale of Investments (Equity / Debt)	0.0	64.8	0.0	0.0	—
+ Acq of Interests in Joint Ventures	45.3	25.1	27.2	0.0	—
+ Acq of Subsidiaries / Businesses (net)	10.6	1,542.9	0.0	0.0	—
+ Disp of Subsidiaries / Businesses (net)	0.0	0.0	0.0	3.5	—
+ Investment in Partnership Firms / LLPs	0.0	0.0	6.3	0.0	—
+ Loans & Advances Made	173.0	-21.2	24.8	27.9	—
+ Loans & Advances Repaid	137.4	2.0	32.1	11.3	—
+ Interest Received — Investing	54.2	80.9	24.0	31.5	—
+ Other Inflows / (Outflows) — Investing	-229.3	510.0	-97.1	51.8	—
Cash from Investing Activities	-725.0	-1,291.8	-869.5	-246.8	—
Cash from Financing Activities
+ Proceeds from Borrowings	686.0	-180.1	218.4	-77.8	—
+ Repayment of Borrowings	28.3	176.8	311.6	525.2	—
+ Payment of Lease Liabilities	7.5	10.7	18.0	22.4	—
+ Payment of Finance Lease Liabilities	1.7	2.5	—	—	—
+ Interest Paid	39.8	131.7	70.2	75.7	—
+ Dividends Paid	101.5	50.7	101.5	52.4	—
Cash from Financing Activities	507.2	-552.6	-283.0	-753.5	—
Net Changes in Cash (pre-FX)	588.1	-899.7	168.8	141.7	—
Net Changes in Cash	588.1	-899.7	168.8	141.7	—
Closing Cash	1,579.0	755.8	—	—	—
Reference Items
EBITDA	926.8	1,321.2	1,726.1	1,978.6	2,231.7
EBITDA Margin %	14.84	17.15	19.31	20.51	22.04
Free Cash Flow (CFO − Capex)	311.3	533.4	545.8	489.7	489.7
Free Cash Flow to Equity	—	331.6	389.8	-183.8	—
Free Cash Flow per Basic Share	12.27	21.02	21.51	19.30	19.30
Price to Free Cash Flow	—	—	—	—	100.01
Cash Flow to Net Income	1.68	1.81	1.68	0.96	—
Cash Paid for Taxes	223.7	296.3	361.3	414.0	—
Cash Paid for Interest	39.8	131.7	70.2	75.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.